ClinicalTrials.gg
Sign In
CompletedNCT02924532Updated Jun 18, 2026

Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy

An observational study in Hypoparathyroidism, sponsored by Centre Hospitalier Universitaire de Nīmes. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this study is to establish an optimal threshold Early parathormon (PTH) assay in order to exclude hypoparathyroidism , that is to say to obtain a negative predictive value of hypoparathyroidism highest possible.

02

Conditions studied

  • Hypoparathyroidism

Browse trials for

03

In context

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

This study's enrollment of 300 is above the median of 147 across 48 observational studies indexed under Hypoparathyroidism.

Browse Hypoparathyroidism studies →

Lead sponsor

Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 90 are open to participants now.

Browse Centre Hospitalier Universitaire de Nīmes studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Included patients underwent total thyroidectomy from 1 February 2012 to 1 December 2013 at the Nîmes University Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients consecutively operated on between February 1, 2012 and December 1, 2013
  • Total thyroidectomy +/- lymphadenectomy
  • Respect of clinicobiological protocol presented above
  • The ( the ) patient ( e) was informed ( e) on the implementation of the study 's objectives, constraints and patient rights
  • The ( the ) patient ( e) is under ( e) at least 18 years

Exclusion criteria

Exclusion Criteria:

  • The ( the ) patient ( e) is under guardianship, curatorship or under guard saves justice
  • It is not possible to give to ( the ) patient ( e) informed information
  • History of cervical radiotherapy
  • Previous history of dysfunction of the parathyroid glands
  • Previous history of surgery of the parathyroid glands
  • A history of kidney failure or hepatocellular
  • History of osteomalacia or Paget's disease
  • unhealed cancer antecedent
  • History of sarcoidosis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with total thiroidectomy

    Biological: immediate post operative bioassay of Parathyroid Hormone

Interventions

  • Biologicalimmediate post operative bioassay of Parathyroid Hormone
06

What researchers measure

Primary outcomes

  1. the presence/absence of hypoparathyroidism

    hypoparathyroidism is defined as: corrected serum calcium Day 1 \<1.90 and / or symptoms of hypocalcemia (cramps, tingling of the extremities and peri-oral) to Day 1 authenticated by a VAS score\> 3.

    Time frame: day 1

07

Study locations

1 site
  • CHU de Nîmes
    Nîmes, Gard 30029, France
08

References and documents

Publications

  • Galy-Bernadoy C, Lallemant B, Chambon G, Pham HT, Reynaud C, Alovisetti C, Bonduelle Q, Guedj AM, Lumbroso S, De Brauwere DP. Parathyroid Hormone Assays following Total Thyroidectomy: Is There a Predictive Value? Eur Thyroid J. 2018 Jan;7(1):34-38. doi: 10.1159/000484689. Epub 2017 Dec 7. PubMed 29594052 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02924532
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
Feb 2012
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Jun 18, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypoparathyroidism →

Other studies from this sponsor

Centre Hospitalier Universitaire de Nīmes →

Start the discussion